Skip to main content
. 2017 May 26;4(7):491–505. doi: 10.1002/acn3.424

Table 2.

Summary of adverse or unanticipated events

No. Events Suramin (N = 5) CTCAEa grade Placebo (N = 5) CTCAEa grade P valueb
1 Asymptomatic rash 5 1 0 0.0079
2 Uncomplicated URIc 2 1 2 1 0.99
3 Headache 1 1 0 0.99
4 Emesis × 1 1d 1 1e 1 0.99
5 Hyperactivity 2f 1 1 1 0.99
6 Hypoglycemiaf 1 2 1 2 0.99
7 Leukocytosis 0 1g 1 0.99
8 Enuresis 1h 1 0 0.99
9 Peripheral neuropathy 0 0 0.99
Total: 13 6 0.12
Nonrash AEs: 8 6 0.77
a

CTCAE, common terminology criteria for adverse events v4.03. Mild to moderate = Grades 1–2; Serious = Grades 3–5.

b

Fisher's exact test.

c

URI, upper respiratory tract infection, common cold. Infusions occurred October–February.

d

In 7‐year‐old after pizza and slushee consumption after playing youth league basketball.

In a 6‐year‐old after a car ride.

e

In a 5‐ and 14‐year‐old intermixed with periods of calm focus in first week (the 14‐year‐old) or first 3 weeks (the 5‐year‐old).

f

Six weeks after the infusion, after several days of a URI and fasting before lunch. Hypoglycemia was asymptomatic and corrected after a normal lunch.

g

Leukocytosis (12.2k WBC) occurred on the day of the saline infusion and preceded a URI.

h

In a 7‐year‐old briefly for a few days while sick with a cold. None of the events required medical intervention. No serious adverse events (SAEs) occurred in this study.